BioRestorative Therapies, Inc. (NASDAQ:BRTX) Sees Significant Decrease in Short Interest

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totalling 46,200 shares, a drop of 8.2% from the September 30th total of 50,300 shares. Currently, 0.9% of the shares of the stock are short sold. Based on an average trading volume of 24,100 shares, the days-to-cover ratio is presently 1.9 days.

BioRestorative Therapies Trading Up 2.0 %

Shares of BRTX opened at $1.56 on Friday. BioRestorative Therapies has a 1-year low of $1.03 and a 1-year high of $3.67. The firm has a fifty day simple moving average of $1.64 and a two-hundred day simple moving average of $1.58.

BioRestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.06. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative return on equity of 107.65% and a negative net margin of 6,898.28%. During the same quarter last year, the company earned ($0.77) earnings per share. As a group, analysts forecast that BioRestorative Therapies will post -1.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Roth Mkm boosted their price objective on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th.

Hedge Funds Weigh In On BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. StoneX Group Inc. purchased a new stake in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned approximately 0.51% of BioRestorative Therapies as of its most recent SEC filing. Institutional investors and hedge funds own 69.38% of the company’s stock.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.